Advances in schizophrenia

Nature Medicine

Volumn 7, Issue 6, 2001, Pages 667-671

  Thaker, G K ^a   Carpenter W T , Jr ^a  

^a UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL FEATURE; GENOME; HUMAN; MOLECULAR GENETICS; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; BRAIN; BRAIN CHEMISTRY; DOPAMINE; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; LINKAGE (GENETICS); PHENCYCLIDINE; RISK FACTORS; SCHIZOPHRENIA;

EID: 0034948739     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/89040     Document Type: Review

References (54)

1. Increased striatal dopamine transmission in schizophrenia: Confirmation in a second cohort
2. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method
3. Schizophrenia and glutamatergic transmission
4. D1 dopamine receptor immunoreactivity in human and monkey cerebral cortex: Predominant and extrasynaptic localization in dendritic spines
5. Regional, cellular, and subcellular variations in the distribution of D1 and D5 dopamine receptors in primate brain
6. Dopamine receptors and groups I and II mGluRs cooperate for long-term depression induction in rat prefrontal cortex through converging postsynaptic activation of MAP kinases
7. Dopamine D1/DS receptor modulation of excitatory synaptic inputs to layer V prefrontal cortex neurons
8. Presynaptic regulation of recurrent excitation by D1 receptors in prefrontal circuits
9. Emerging principles of altered neural circuitry in schizophrenia
10. The neuropathology of schizophrenic diseases: Historical aspects and present knowledge
11. Volumetric measure of the frontal and temporal lobe regions in schizophrenia: Relationship to negative symptoms
12. The reduced neuropil hypothesis: A circuit based model of schizophrenia
13. Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia
14. Antipsychotic treatment induces alterations in dendrite- and spine-associated proteins in dopamine-rich areas of the primate cerebral cortex
15. Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex
16. Adult schizophrenia following prenatal exposure to an influenza epidemic
17. Retroviral RNA identified in the cerebrospinal fluids and brains of individuals with schizophrenia
18. Schizophrenia: Genetics
19. The genetic epidemiology of schizophrenia in a Finnish twin cohort. A population-based modeling study
20. Schizophrenia: A review of genetic studies
21. Search for schizophrenia susceptibility genes
22. Defining the schizophrenia phenotype
23. Deficit and nondeficit forms of schizophrenia: The concept
24. Antecedents, symptom progression, and long-term outcome of the deficit syndrome in schizophrenia
25. Borna disease virus antibodies and the deficit syndrome of schizophrenia
26. A separate disease within the syndrome of schizophrenia
27. Sibling correlation of deficit syndrome in the Irish study of high-density schizophrenia families
28. Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome
29. Strong inference, theory testing, and the neuroanatomy of schizophrenia
30. Eye-tracking patterns in schizophrenia
31. Eye tracking dysfunction is a putative phenotypic susceptibility marker of schizophrenia and maps to a locus on chromosome 6p in families with multiple occurrence of the disease
32. Neuropsychological functioning in siblings discordant for schizophrenia and healthy volunteers
33. Hippocampal N-acetyl aspartate in unaffected siblings of patients with schizophrenia: A possible intermediate neurobiological phenotype
34. Alternative phenotypes for the complex genetics of schizophrenia
35. Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus
36. Schizophrenia and 15q14
37. Effect of chlorpromazine and haloperidol of formation of 3- methoxytyramine and normetanephrine in mouse brain
38. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine
39. Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia
40. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia
41. Disease-specific changes in regulator of G-protein signaling 4 (RGS4) expression in schizophrenia
42. Location of a major susceptibility locus for familial schizophrenia on chromosome 1q21-q22
43. Localization of a susceptibility locus for schizophrenia on chromosome 5
44. Eye tracking dysfunction is a putative phenotypic susceptibility marker of schizophrenia and maps to a locus on chromosome 6p in families with multiple occurrence of the disease
45. Genetic heterogeneity in schizophrenia: Stratification of genome scan data using co-segregating related phenotypes
46. A high-density genome scan detects evidence for a bipolar-disorder susceptibility locus on 13q32 and other potential loci on 1q32 and 18p11.2
47. Linkage of a composite inhibitory phenotype to a chromosome 22q locus in eight Utah families
48. Velo-cardio-facial syndrome associated with chromosome 22 deletions encompassing the DiGeorge locus
49. A genome survey indicates a possible susceptibility locus for bipolar disorder on chromosome 22
50. Genetics of schizophrenia and the new millennium: Progress and pitfalls
51. Effect of COMT va1108/158met genotype on frontal lobe function and risk for schizophrenia
52. Are schizophrenic and bipolar disorders related? A review of family and molecular studies